(function(){var loadHandler=window['sl_{2C9CB988-3790-4A21-B3F6-F512CAAA85F6}'];loadHandler&&loadHandler(0, '<div id="spr0_63034"><div id="spr1_63034" class="kern"><img id="img57_63034" src="data/img51.jpg" width="1024px" height="768px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_63034" class="kern"><div id="spr3_63034" style="left:-2.157px;top:0.104px;"><img id="img0_63034" src="data/img0.jpg" width="1024" height="768" alt="C:\\College\\Dropbox\\Launchpad (2)\\Seebri\\PowerPoint Seebri\\3_2_2 popup.jpg" style="top:-0.104px;"/></div><div id="spr4_63034" style="left:660px;top:593px;"><img id="img1_63034" src="data/img1.png" width="40" height="14" alt="Day 21"/></div><div id="spr5_63034" style="left:345px;top:593px;"><img id="img2_63034" src="data/img2.png" width="32" height="14" alt="Day 1"/></div><div id="spr6_63034" style="left:413.231px;top:353.337px;"><img id="img3_63034" src="data/img3.png" width="562" height="280" alt="C:\\College\\Dropbox\\Launchpad (2)\\Seebri\\PowerPoint Seebri\\PPT_With_Editable_Text\\popup_notrans.png" style="left:-0.066px;top:0.051px;"/></div><div id="spr7_63034" style="left:446px;top:582px;"><img id="img4_63034" src="data/img4.png" width="388" height="26" alt="Treatments were taken once daily in the mornings between 8 AM and 11 AM and patients were tested within 1 hour of dose administration. 6"/></div><div id="spr8_63034" style="left:443px;top:380px;"><img id="img5_63034" src="data/img5.png" width="502" height="118" alt="GLOW2 (GLYCOPYRRONIUM BROMIDE IN COPD AIRWAYS-2): A 52-week treatment, randomized, double-blinded, placebo-controlled, with open-label tiotropium 18 µg, parallel-group study to assess the efficacy, safety, and tolerability of once-daily glycopyrronium 50 µg in 1066 patients (glycopyrronium n=529, open-label tiotropium n=268, placebo n=269) with chronic obstructive pulmonary disease. The primary objective was to confirm that glycopyrronium compared with placebo significantly increase mean 24-hour post-dose (trough) FEV1  following 12 weeks of treatment in patients with moderate to severe COPD. As exploratory analyses, open-label tiotropium was comapared with glycopyrronium and placebo for all study objectives.5"/></div><div id="spr9_63034" style="left:447px;top:520px;"><img id="img6_63034" src="data/img6.png" width="356" height="26" alt="For information on Seebri Breezhaler dose expression, please refer to full prescribing information."/></div><div id="spr10_63034" style="left:690.94px;top:177.057px;"><div id="svg0_63034" style="left:0px;top:0px;"><svg width="137" height="16" viewBox="0 0 137 16"><path fill="none" d="M0,0 h136.1 v15.347 h-136.1 Z"/></svg></div><div id="spr11_63034" style="left:4.06px;top:2.943px;"><img id="img7_63034" src="data/img7.png" width="128" height="9" alt="Once-daily Seebri Breezhaler (n=95)1"/></div><div id="svg1_63034" style="top:18.002px;"><svg width="101" height="16" viewBox="0 0 101 16"><path fill="none" d="M0,0 h100.174 v15.347 h-100.174 Z"/></svg></div><div id="spr12_63034" style="left:5.06px;top:20.943px;"><img id="img8_63034" src="data/img8.png" width="57" height="9" alt="Placebo (n=95)1"/></div></div><div id="spr13_63034" style="left:865px;top:652px;"><img id="img9_63034" src="data/img9.png" width="76" height="14" alt="Study Design"/></div><div id="spr14_63034" style="left:865px;top:652px;"><img id="img10_63034" src="data/img10.png" width="76" height="14" alt="Study Design"/></div><div id="svg2_63034" style="left:827.041px;top:635.132px;"><svg width="155" height="48" viewBox="0 0 155 48"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h154.561 v47.995 h-154.561 Z"/></svg></div><div id="spr15_63034" style="left:157px;top:287px;"><img id="img11_63034" src="data/img11.png" width="13" height="196" alt="Modified Borg Dyspnea Score† (P&lt;0.05)"/></div><div id="spr16_63034" style="left:312px;top:245px;"><img id="img12_63034" src="data/img12.png" width="104" height="10" alt="Improvement vs placebo"/></div><div id="spr17_63034" style="left:626px;top:279px;"><img id="img13_63034" src="data/img12.png" width="104" height="10" alt="Improvement vs placebo"/></div><div id="spr18_63034" style="left:407.841px;top:615.834px;"><img id="img14_63034" src="data/img13.png" width="545" height="19" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\popup_banner1.png" style="left:-0.168px;top:0px;"/></div><div id="spr19_63034" style="left:942.984px;top:357.543px;"><img id="img15_63034" src="data/img14.png" width="11" height="6" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\flyout_down_0.png" style="left:0.001px;top:-0px;"/></div><div id="spr20_63034" style="left:930.822px;top:623.793px;"><img id="img16_63034" src="data/img15.png" width="11" height="6" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_rapid_3_1_1_PROJECTCODE\\global_seebri_en_rapid_3_1_1_PROJECTCODE\\local\\global_seebri_en_rapid_3_1_1_PROJECTCODE\\assets\\flyout_up.png" style="left:0.001px;top:-0px;"/></div><div id="svg3_63034" style="left:920.301px;"><svg width="104" height="135" viewBox="0 0 104 135"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h103.699 v134.55 h-103.699 Z"/></svg></div><div id="svg4_63034" style="left:827.041px;top:623.793px;"><svg width="162" height="63" viewBox="0 0 162 63"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h161.31 v62.57 h-161.31 Z"/></svg></div><div id="spr21_63034" style="left:62px;top:96px;"><img id="img17_63034" src="data/img16.png" width="550" height="15" alt="Significantly improved shortness of breath during exertion vs placebo at both day 1 and 214,6"/></div><div id="spr22_63034" style="top:0.104px;"><img id="img18_63034" src="data/img17.jpg" width="1024" height="768" alt="C:\\College\\Dropbox\\Launchpad (2)\\Seebri\\PowerPoint Seebri\\3_2_2.jpg" style="top:-0.104px;"/></div><div id="spr23_63034" style="top:0.104px;"><img id="img19_63034" src="data/img18.png" width="1024" height="768" alt="C:\\College\\Dropbox\\Launchpad (2)\\Seebri\\PowerPoint Seebri\\3_2_2_chart.png" style="top:-0.104px;"/></div><div id="spr24_63034" style="left:104px;top:175px;"><img id="img20_63034" src="data/img19.png" width="516" height="38" alt="Significantly improved shortness of breath during exertion vs placebo at both day 1 and 214,6"/></div><div id="spr25_63034" style="left:89px;top:129px;"><img id="img21_63034" src="data/img20.png" width="747" height="17" alt="In GLOW3, a 3-week trial designed to measure exercise tolerance, Seebri Breezhaler, dosed in the morning 4,6*:"/></div><div id="spr26_63034" style="left:90px;top:43px;"><img id="img22_63034" src="data/img21.png" width="885" height="63" alt="MORNING WITH IMPROVED SHORTNESS OF BREATH DURING EXERTION WITH ONCE-DAILY SEEBRI ® BREEZHALER® COMPARED WITH PLACEBO4,6*"/></div><div id="spr27_63034" style="left:805.62px;top:497.86px;"><div id="svg5_63034" style="left:7.2px;"><svg width="172" height="51" viewBox="0 0 172 51"><path fill="none" d="M0,0 h171.749 v50.079 h-171.749 Z"/></svg></div><div id="spr28_63034" style="left:12.38px;top:7.14px;"><img id="img23_63034" src="data/img22.png" width="150" height="36" alt="EXERCISE \
TOLERANCE BACK 4,6"/></div><div id="svg6_63034" style="top:44.392px;"><svg width="193" height="19" viewBox="0 0 193 19"><path fill="none" d="M0,0 h192.809 v18.578 h-192.809 Z"/></svg></div><div id="spr29_63034" style="left:14.38px;top:50.14px;"><img id="img24_63034" src="data/img23.png" width="159" height="9" alt="WITH ONCE-DAILY SEEBRI BREEZHALER"/></div></div><div id="spr30_63034" style="left:683px;top:503px;"><img id="img25_63034" src="data/img24.png" width="121" height="53" alt="ADD"/></div><div id="spr31_63034" style="left:118px;top:308px;"><img id="img26_63034" src="data/img25.png" width="11" height="175" alt="Modified Borg Dyspnea Score† (P&lt;0.05)"/></div><div id="spr32_63034" style="left:475px;top:718px;"><img id="img27_63034" src="data/img26.png" width="197" height="15" alt="LOCAL PRESCRIBING INFORMATION"/></div><div id="spr33_63034" style="left:493.097px;top:261.101px;"><div id="svg7_63034" style="left:0px;top:0px;"><svg width="137" height="15" viewBox="0 0 137 15"><path fill="none" d="M0,0 h136.1 v14.539 h-136.1 Z"/></svg></div><div id="spr34_63034" style="left:4.903px;top:3.899px;"><img id="img28_63034" src="data/img27.png" width="118" height="8" alt="Once-daily Seebri Breezhaler (n=95)1"/></div><div id="svg8_63034" style="top:12.879px;"><svg width="101" height="15" viewBox="0 0 101 15"><path fill="none" d="M0,0 h100.174 v14.539 h-100.174 Z"/></svg></div><div id="spr35_63034" style="left:5.903px;top:16.899px;"><img id="img29_63034" src="data/img28.png" width="53" height="8" alt="Placebo (n=95)1"/></div></div><div id="spr36_63034" style="left:690px;top:226px;"><img id="img30_63034" src="data/img29.png" width="235" height="25" alt="†Borg dyspnea scale=a simple, linear 10-point scale that reproducibly measures the intensity of breathlessness."/></div><div id="spr37_63034" style="left:690px;top:170px;"><img id="img31_63034" src="data/img30.png" width="206" height="23" alt="*Treatments were taken once daily in the mornings between 8 AM  and 11 AM.6"/></div><div id="spr38_63034" style="left:690px;top:280px;"><img id="img32_63034" src="data/img31.png" width="234" height="24" alt="‡Borg dyspnea scale=a simple, linear 10-point scale that reproducibly measures the intensity of breathlessness."/></div><div id="spr39_63034" style="left:92.357px;top:565.154px;"><img id="img33_63034" src="data/img32.png" width="568" height="286" alt="C:\\College\\Dropbox\\Launchpad (2)\\Seebri\\PowerPoint Seebri\\3_2_2_popup.png" style="left:-0.164px;top:-0.246px;"/></div><div id="spr40_63034" style="left:627.417px;top:572.633px;"><img id="img34_63034" src="data/img15.png" width="11" height="6" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_rapid_3_1_1_PROJECTCODE\\global_seebri_en_rapid_3_1_1_PROJECTCODE\\local\\global_seebri_en_rapid_3_1_1_PROJECTCODE\\assets\\flyout_up.png" style="left:0.001px;top:-0px;"/></div><a id="hl0_63034" href="veeva:gotoSlide(seebri_en_0_0.zip)" title="veeva:gotoSlide(seebri_en_0_0.zip)" target="_blank" onclick="return document.getElementById(\'coreSpr_10089401\').getCore().gotoLink(this);" style="left:0px;top:641.009px;"><div id="svg9_63034" style="left:0px;top:0px;"><svg width="218" height="127" viewBox="0 0 218 127"><path fill="#000000" fill-opacity="0" d="M0,0 h217.116 v126.991 h-217.116 Z"/></svg></div></a><a id="hl1_63034" href="veeva:gotoSlide(seebri_en_10_1_1.zip)" title="veeva:gotoSlide(seebri_en_10_1_1.zip)" target="_blank" onclick="return document.getElementById(\'coreSpr_10089401\').getCore().gotoLink(this);" style="left:313.52px;top:678.804px;"><div id="svg10_63034" style="left:0px;top:0px;"><svg width="131" height="90" viewBox="0 0 131 90"><path fill="#000000" fill-opacity="0" d="M0,0 h130.429 v89.196 h-130.429 Z"/></svg></div></a><a id="hl2_63034" href="veeva:gotoSlide(seebri_en_7_1_1.zip)" title="veeva:gotoSlide(seebri_en_7_1_1.zip)" target="_blank" onclick="return document.getElementById(\'coreSpr_10089401\').getCore().gotoLink(this);" style="left:458.127px;top:680.44px;"><div id="svg11_63034" style="left:0px;top:0px;"><svg width="277" height="90" viewBox="0 0 277 90"><path fill="#000000" fill-opacity="0" d="M0,0 h276.926 v89.196 h-276.926 Z"/></svg></div></a><a id="hl3_63034" href="veeva:gotoSlide(seebri_en_11_0.zip)" title="veeva:gotoSlide(seebri_en_11_0.zip)" target="_blank" onclick="return document.getElementById(\'coreSpr_10089401\').getCore().gotoLink(this);" style="left:827.677px;top:656.127px;"><div id="svg12_63034" style="left:0px;top:0px;"><svg width="197" height="112" viewBox="0 0 197 112"><path fill="#000000" fill-opacity="0" d="M0,0 h196.323 v111.769 h-196.323 Z"/></svg></div></a><div id="svg13_63034" style="left:621.636px;top:136.704px;"><svg width="76" height="86" viewBox="0 0 76 86"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h75.691 v85.447 h-75.691 Z"/></svg></div><div id="spr41_63034" style="left:346px;top:718px;"><img id="img35_63034" src="data/img33.png" width="74" height="15" alt="REFERENCES"/></div><div id="spr42_63034" style="left:545px;top:606px;"><img id="img36_63034" src="data/img34.png" width="76" height="14" alt="Study Design"/></div><div id="spr43_63034" style="left:545px;top:605px;"><img id="img37_63034" src="data/img35.png" width="76" height="15" alt="Study Design"/></div><div id="svg14_63034" style="left:512px;top:585.748px;"><svg width="148" height="52" viewBox="0 0 148 52"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h147.442 v51.481 h-147.442 Z"/></svg></div><div id="svg15_63034" style="left:512px;top:588.095px;"><svg width="148" height="52" viewBox="0 0 148 52"><path fill="#ffffff" fill-opacity="0.012" d="M0,0 h147.442 v51.481 h-147.442 Z"/></svg></div><div id="spr44_63034" style="left:451px;top:331px;"><img id="img38_63034" src="data/img36.png" width="81" height="9" alt="Improvement vs placebo"/></div><div id="spr45_63034" style="left:451px;top:317px;"><img id="img39_63034" src="data/img37.png" width="72" height="13" alt="-1.16(P&lt;0.05)"/></div><div id="spr46_63034" style="left:234px;top:304px;"><img id="img40_63034" src="data/img36.png" width="81" height="9" alt="Improvement vs placebo"/></div><div id="spr47_63034" style="left:208.09px;top:364.328px;"><img id="img41_63034" src="data/img38.png" width="353" height="177" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\1_bars.png" style="left:0.029px;top:-0.01px;"/></div><div id="spr48_63034" style="left:225.193px;top:348.598px;"><img id="img42_63034" src="data/img39.png" width="317" height="131" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\2_numbers.png" style="left:0.026px;top:0.243px;"/></div><div id="spr49_63034" style="left:234.635px;top:320.96px;"><img id="img43_63034" src="data/img40.png" width="1" height="108" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\3_1_line.png" style="left:0px;top:-0.006px;"/></div><div id="spr50_63034" style="left:235.474px;top:320.192px;"><img id="img44_63034" src="data/img41.png" width="70" height="1" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\3_2_line.png" style="left:0.006px;top:-0px;"/></div><div id="spr51_63034" style="left:472px;top:551px;"><img id="img45_63034" src="data/img42.png" width="34" height="11" alt="Day 21"/></div><div id="spr52_63034" style="left:256px;top:553px;"><img id="img46_63034" src="data/img43.png" width="27" height="11" alt="Day 1"/></div><div id="spr53_63034" style="left:452.636px;top:347.465px;"><img id="img47_63034" src="data/img40.png" width="1" height="108" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\3_1_line.png" style="left:0px;top:-0.006px;"/></div><div id="spr54_63034" style="left:453.701px;top:347.356px;"><img id="img48_63034" src="data/img44.png" width="71" height="1" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\5_2_line.png" style="left:-0.244px;top:-0px;"/></div><div id="spr55_63034" style="left:304.069px;top:320.132px;"><img id="img49_63034" src="data/img45.png" width="1" height="23" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\3_3_line.png" style="left:0px;top:0.249px;"/></div><div id="spr56_63034" style="left:524.034px;top:348.222px;"><img id="img50_63034" src="data/img46.png" width="1" height="17" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\5_3_line.png" style="left:0.001px;top:-0.237px;"/></div><div id="spr57_63034" style="left:99.919px;top:308.992px;"><img id="img51_63034" src="data/img3.png" width="562" height="280" alt="C:\\College\\Dropbox\\Launchpad (2)\\Seebri\\PowerPoint Seebri\\PPT_With_Editable_Text\\popup_notrans.png" style="left:-0.066px;top:0.051px;"/></div><div id="spr58_63034" style="left:630.537px;top:312.189px;"><img id="img52_63034" src="data/img14.png" width="11" height="6" alt="C:\\Work\\Seebri Global Assets\\137261 HTML files\\137261 HTML files\\SeebriHidden\\global_seebri_en_improved_3_2_2_PROJECTCODE\\global_seebri_en_improved_3_2_2_PROJECTCODE\\local\\global_seebri_en_improved_3_2_2_PROJECTCODE\\assets\\flyout_down_0.png" style="left:0.001px;top:-0px;"/></div><div id="spr59_63034" style="left:121px;top:518px;"><img id="img53_63034" src="data/img47.png" width="390" height="26" alt="Treatments were taken once daily in the mornings between 8 AM and 11 AM. and patients were tested within 1 hour of dose administration. 6"/></div><div id="spr60_63034" style="left:120px;top:330px;"><img id="img54_63034" src="data/img48.png" width="502" height="118" alt="GLOW2 (GLYCOPYRRONIUM BROMIDE IN COPD AIRWAYS-2): A 52-week treatment, randomized, double-blinded, placebo-controlled, with open-label tiotropium 18 µg, parallel-group study to assess the efficacy, safety, and tolerability of once-daily glycopyrronium 50 µg in 1066 patients (glycopyrronium n=529, open-label tiotropium n=268, placebo n=269) with chronic obstructive pulmonary disease. The primary objective was to confirm that glycopyrronium compared with placebo significantly increase mean 24-hour post-dose (trough) FEV1  following 12 weeks of treatment in patients with moderate to severe COPD. As exploratory analyses, open-label tiotropium was comapared with glycopyrronium and placebo for all study objectives.5"/></div><div id="spr61_63034" style="left:122px;top:471px;"><img id="img55_63034" src="data/img49.png" width="356" height="26" alt="For information on Seebri Breezhaler dose expression, please refer to full prescribing information."/></div><div id="spr62_63034" style="left:235px;top:293px;"><img id="img56_63034" src="data/img50.png" width="72" height="13" alt="-0.92(P&lt;0.05)"/></div></div></div>');})();